Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Private label Advil PM on the way

This article was originally published in The Tan Sheet

Executive Summary

Perrigo is shipping ibuprofen and diphenhydramine citrate tablets (200/38 mg) to retailers, the Allegan, Mich.-based firm says Feb. 20. The store-brand nighttime sleep aid and pain reliever compares to Wyeth's Consumer Healthcare Advil PM tablets, which sold about $70 million in the 12 months ending Sept. 28, 2008, Perrigo says (1"The Tan Sheet" Nov. 3, 2008, In Brief)

You may also be interested in...

Perrigo readies ibuprofen/PM launch

The company says Oct. 29 it expects final clearance to launch a private-label version of Wyeth Consumer Healthcare's Advil PM tablets after Wyeth's exclusivity ends, Dec. 21, 2008. FDA granted tentative approval for Perrigo's abbreviated new drug application for the non-steroidal anti-inflammatory drug (ibuprofen 200 mg and diphenhydramine citrate 38 mg) indicated as a pain reliever and sleep-aid. According to Allegan, Mich.-based Perrigo, Advil PM U.S. sales totaled $70 million in the 12 months ending Sept. 28. Perrigo includes sales of an ibuprofen/diphenhydramine citrate product in the $275 million it expects to generate from more than 25 products launched between February 2007 and June 2009 (1"The Tan Sheet" Aug. 25, 2008, p. 11)

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts